28
Abstracts
Alveolar cleft management: current status
R.S. Kisnisci
Ankara University, Ankara, Turkey
Alveolar cleft reconstruction has become an established surgi-
cal technique over the last few decades. In the past it was an
overlooked and even a neglected area of concern in cleft cases.
As in many aspects of clefting disorders, alveolar cleft recons-
tructive approaches have also some diversity in the details in
overall management protocol. Early or late repair with or with-
out grafting may be selected however alveolar grafting is the most
commonly used technique to deal with the defect but yet timing,
grafting options, and finishing stage may reveal various opinions.
The objectives of a successful management includes uniformity
and continuity of the segments, three-dimensional and stable
reconstruction as well as taking into consideration of soft tissue
quality of the repaired area for optimal periodontal, orthodontic
and rehabilitation in the long-term.
This presentation will discuss current information on primary
and secondary management and details in regards to pitfalls and
shortcomings to obtain most favourable outcome.
http://dx.doi.org/10.1016/j.ijom.2017.02.103Primary alveolar cleft management — current considerations
R.S. Kisnisci
Ankara University, Ankara, Turkey
Surgical repair of alveolar clefts constitute an integral part in the
overall management of clefting disorders. Despite general require-
ments laid down for a successful outcome there are controversies
essentially based on surgical timing.
Among main objectives to restore the alveolar bone conti-
nuity enabling dental eruption through disrupted segments is
required. The factors that may be considered involves diversity
of assessments and reconstruction options that largely dictates
by craniofacial development, orofacial cleft anatomy, bone repair
physiology, and detailed operative techniques.
Generally alveolar cleft repair strategies may fall into early or
late management techniques. Early surgical management entails
closure of the area with or without bone grafting in order to recon-
struct the clefting disorder as early as possible. Late surgical
management as a secondary repair varies between chronologi-
cal ages and dentition stages. Primary alveolar cleft management
though not widely practiced may obviate certain shortcomings
related to late closures. On the other hand the approach itself has
issues that need to be considered. The presentation will be based
on personal clinical cases and recent literature related to primary
alveolar cleft management.
http://dx.doi.org/10.1016/j.ijom.2017.02.104Spontaneous lung metastasis of humanMerkel cell lines trans-
planted into severe combined immunodeficiency mice
J. Knips
University Medical Center Hamburg, Hamburg, Germany
Background:
Merkel cell carcinoma (MCCs) is a well-known
aggressive tumour of the skin that frequently leads to early death
due to its high propensity to metastasise. In the last years Merkel
cell polyoma virus (MCPyV) has been detected in the majority of
MCCs, however, no clinically important differences in the clini-
cal course of MCC due to the presence of the MCPyV has been
observed.
Methods:
The two MCPyV positive human MCC cell lines,
WaGa and MKL-1 were subcutaneously engrafted in severe com-
bined immunodeficiency (SCID) mice. Circulating tumour cells
(CTCs) in blood, bone marrow and lungs were quantified by Alu
quantitative polymerase chain reaction (qPCR). Spontaneous lung
metastases were also quantified by histology. In addition, several
markers typical for MCCs were immunohistochemically detected
in the xenograft model.
Results:
In WaGa mice, mean survival was 62 days whereas
mean survival was 108 days in MKL-1 mice. The lungs were
also histologically examined for the number of lung metastases
showing more metastases in the WaGa mice than in the MKL-1
mice corroborating the Alu qPCR data. Histologically 12.145 lung
metastases were found and 68.813 tumour cells in the lung were
detected by qPCR in WaGa mice. In MKL-1, 2.014 lung metas-
tases were found histologically and 15.858 metastatic cells were
detected by qPCR.
Conclusion:
A high and a low spontaneous metastasis model for
human MCCs in SCID mice were established whereby the high
metastatic WaGa model was the biologically more aggressive one
with a shorter survival than the lower metastatic MKL-1 model
thus reflecting the clinical situation.
http://dx.doi.org/10.1016/j.ijom.2017.02.105Refined autogenous fat grafting as a de novo treatment of oral
submucous fibrosis
E.C. Ko
∗
, T.M. Lin
Kaohsiung Medical University, Kaohsiung, Chinese Taipei
Background:
Submucous fibrosis, is associated with the use of
betel nut-slake lime preparations. This entity may be severe and
produce a significant limitation of jaw opening. Approaches using
injections of steroids, chymotrypsin, hyaluronidase or alcohol, and
surgeries using mucosal or nonvascularised split-thickness skin
grafts have not only been ineffective but have often worsened
the condition with added scar tissue. Total excision with soft tis-
sue myocutaneous or free microvascular flaps transposing viable
elastic skin shows good result but with morbidity of the donor site.
Objectives:
This is a retrospective study on the effect of autoge-
nous fat grafting by using MAFT
®
Gun for fat injection, which
comprises an important part of our protocol in treating oral sub-
mucous fibrosis.
Methods:
Our Kaohsiung Medical University protocol includes
coronoidotomies, injection of the fat grafting by using MAFT
®
gun (1/30–1/240 mL), stripping off the temporalis muscle and
tendon from the ramus, mouth opening exercise, postoperative
acupuncture.
Findings and Conclusion:
All five patients were found with
average increase in mouth opening, as 18
±
4 mm at six-months
follow-up. Visual analogue scale score of pain also significantly
reduced significantly within few days following surgery. This graft
technique also shows increased elasticity and hence with high
affinity to the recipient sites. Increased elastin was found within
the postoperative mucosa. This refined autogenous fat is very help-
ful in regaining the vermillion border as well as lip augmentation.
This really shed a new light on the treatment of submucous fibrosis.
http://dx.doi.org/10.1016/j.ijom.2017.02.106




